This study aimed to investigate the relationship of anklebrachial index (ABI) with all-cause mortality and cardiovascular (CV) mortality in Chinese inpatients after 3 years of follow-up. All the participants were inpatients at high risk of atherosclerosis and enrolled from July to November 2004. A total of 3210 patients were followed up until an end point was reached or until February 2008. The mean follow-up time was 37.65±1.54 months. Patients with ABI p0.4 were significantly older than other ABI categories (Po0.001) at baseline. The all-cause and CV disease (CVD) mortality were highest (37.7 and 27.5%, respectively) after a 3-year follow-up in patients with ABI p0.4. There was a significant increasing tendency in mortality with decreasing ABI levels (Po0.001). The Kaplan-Meier curves of survival showed a decreasing survival rate with the ABI decreasing, not only for all-cause mortality but also for CVD mortality (Po0.001). Adjusted for other risk factors, patients with ABI p0.4 were 3.105 times (95% CI 1.936-4.979) as likely to die as those with ABI in the range of 1.00-1.4; patients with ABI p0.4 were about five times (95% CI 2.740-8.388) as likely to die of CVD as those with ABI in the range of 1.00-1.4. Even patients with ABI in the range of 0.41-0.90 were more than 1.5 times as likely to die (relative risk ¼ 1.534, 95% CI 1.199-1.962), or die of CVD (relative risk ¼ 2.031, 95% CI 1.479-2.789) as those with ABI in the range of 1.00-1.4. Low ABI is related to a higher all-cause and CV mortality compared with normal ABI. ABI as a marker of atherosclerosis should be routinely evaluated to assess the risk of CV mortality in Chinese patients.
Introduction
Peripheral arterial disease (PAD), caused by atherosclerotic occlusion in the arteries of the legs, is an important manifestation of systemic atherosclerosis. The prevalence of PAD is different in different reports;
1,2 the age-adjusted prevalence of PAD is approximately 12%. 3 The early diagnosis of PAD remains an important step to reduce death risk. Ankle-brachial index (ABI), a ratio of ankle systolic blood pressure to brachial systolic pressure, is widely used in clinical practice to assess the potency of the lower arterial system and to screen for PAD. The ABI threshold of 0.9 has a sensitivity of 95% and a specificity of 100% compared with angiography. 4 The potential value of the ABI has been well explained by epidemiological and clinical studies. 3, 5, 6 Low ABI levels are associated with cardiovascular (CV) risk factors and coronary artery disease. 6, 7 McKenna et al. 8 documented a 5-year mortality of approximately 30 and 50% in patients with an ABI of 0.70 and 0.40, respectively. The relationship between ABI and morbidity and mortality in patients with lower extremity PAD has also been quantitated by Sikkink et al. However, there were no data focused on Chinese PAD patients and on the associations of ABI with all-cause mortality and CV mortality in China. In 2004, The China ABI Cohort Study first began to investigate the baseline characteristics of Chinese PAD patients, who were followed up to 3 years. This paper is prompted to examine the relationship of ABI with all-cause and CV mortality in China.
Methods

Study participants
The China ABI Cohort Study, designed in 2004, is the first study that focused on PAD in the Chinese population. All the participants were hospitalized patients over 35 years old with two or more CV risk factors, and were enrolled from eight university hospitals in Shanghai and Beijing from July to November 2004. Risk factors included smoking, diabetes mellitus, hypertension, dyslipidemia, stroke and history of coronary artery disease (CAD). Exclusion criteria included severe heart failure, liver failure, renal failure or cancer. Finally, a population of 3732 patients, aged X35 years, including 1979 men and 1753 women who had complete baseline data, were entered in the cohort. They were followed up until an end point (death) was reached or until February 2008. This study was approved by the ethics committee of Tongji University and informed consent was obtained from the participants.
ABI measurement and classification
The details of ABI measurement was shown in our previous paper. 10, 11 An ABI 41.4 could be related to poor arterial compressibility resulting from stiffness and calcification, and we exclude those with ABI 41.4. An ABI p0.9 in either leg was considered as evidence of PAD. The ABI was categorized as: p0.4, 0.41-0.90, 0.91-0.99 and 1.00-1.4 to show the relationship with all-cause and CVD mortality. 12 Identification of all-cause and CV death Death was identified by hospitals records or by contacting the participants' families. Further causes of death were investigated by using medical records and informant interviews. All materials were reviewed independently by a physician of the ABI cohort study to confirm the cause of death. CV death is defined as death due to coronary heart disease or stroke.
Statistical analysis
Continuous variable, such as age, was presented as mean ± s.d. Categorical variables were expressed as a percentage. Participants were classified into four categories according to ABI value. Independent samples ANOVA (analysis of variance) and the w 2 -test were used to compare continuous and categorical differences at baseline. The KaplanMeier model was used to calculate the cumulative mortality rate from all-cause and CVD among the four categories. Cox regression model was used to estimate the independent relationship between ABI and all-cause and CV mortality, after adjusting for gender, age, CAD, hypertension, stroke, diabetes mellitus, smoking, chronic renal disease and dyslipidemia. A P-value of o0.05 was considered significant. All analyses were performed with SPSS (Statistics Package for Social Science) version 13.0.
Results
A total of 3732 participants with available baseline data were enrolled in the cohort. Of these, 969 participants (26.0%) were diagnosed as PAD by ABI. There were 82, 887, 507 and 2256 patients with ABI p0.4, 0.41-0.90, 0.91-0.99 and 1.00-1.4, respectively.
During a mean follow-up time of 37.65 ± 1.54 months, 522 participants (14%) were lost during the follow-up because of the changes of telephone number or family address. Among those missing participants, there were 13, 137, 52 and 320 patients with ABI p0.4, 0.41-0.90, 0.91-0.99 and 1.00-1.4, respectively. After careful calculation, the missing participants did not significantly affect the major results of this study. There were 3210 participants with complete data up to 3 years of follow-up. Table 1 showed the baseline characteristics in the four ABI categories. Patients with ABI p0.4 were significantly older than those with other ABI categories (Po0.001) at baseline. The prevalence of CAD, hypertension, diabetes and stroke tended to increase with decreasing ABI levels. Abbreviations: ABI, ankle-brachial index; CAD, coronary artery disease; CVD, cardiovascular disease.
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As shown in Table 2 , patients with ABI p0.4 had the highest all-cause and CVD mortality (37.7 and 27.5%, respectively) after 3 years of follow-up. There was a significant increasing tendency in mortality with decreasing ABI levels (both Po0.001).
Figures 1a and b illustrated the relationship between the four ABI categories and all-cause mortality and CVD mortality. The univariate Kaplan-Meier curves of survival showed the survival rate decreasing with the ABI decreasing, not only for all-cause mortality but also for CVD mortality. 
Discussion
Cardiovascular disease remains to be the most common cause of death and medical burden reported by the Ministry of Health in China, even in the whole world. How to accurately identify CVD or those at risk remains a serious public health challenge. The ABI has been suggested as a useful predictor of generalized atherosclerosis; individuals with a low ABI have an increased risk of death from CVD in epidemiological studies. 8, [13] [14] [15] [16] [17] [18] [19] [20] ABI was widely used to predict CVD morbidity and mortality. However, all the clinical data came from foreign countries. There was no prospective study in China focused on ABI and mortality. This is the first large-scale prospective ABI cohort study, focused on the Chinese population, to evaluate the relationship between ABI and mortality. A prevalence of 26% of PAD in high-risk patients was reported at baseline in our previous research. 10 Compared with those with ABI of 1.00-1.4, those with ABI p0.4 coexist significantly with a variety of CVD risk factors, such as a higher prevalence of hypertension, diabetes and stroke. There was an increasing tendency in the prevalence of hypertension, diabetes, and coronary artery disease with ABI decreasing at baseline ( Table 1 ). The ARIC (Atherosclerosis Risk in Communities) study also reported the same tendency on hypertension, diabetes and smoking. 21 After a 3-year follow-up, those with ABI p0.4 had the highest all-cause (37.7%) and CVD mortality (27.5%). The mortality decreased with increase in ABI, not only for all-cause mortality but also for CVD mortality. McKenna et al. 8 reported that 5-year mortality was 50% in patients with an ABI of 0.4 and 30% in patients with an ABI of 0.70. Although the follow-up period is only about 3 years, our research showed a 3-year all-cause mortality of 37.7% in patients with ABI p0.4 and 24.4% in patients with ABI of 0.41-0.90. The two researches had almost the same results. However, with this estimation, the 5-year mortality of our population may be higher than McKenna's after long time follow-up.
The Kaplan-Meier curve of survival of our research showed the survival rate decreasing significantly with the ABI decreasing ( Figure 1 ). Sikkink et al.'s research showed that the cumulative survival after 5 years was 63% for patients with ABI o0.50, 71% for patients with ABI of 0.50-0.69 and 91% for those with ABI of 0.70-0.89. 9 The research proves that patients with low ABI value have a high mortality rate compared with those with a normal ABI value.
After adjusting for gender, age, CAD, hypertension, stroke, diabetes mellitus, smoking, chronic renal disease and dyslipidemia, the relative risk increased with decreasing ABI for both all-cause and CV mortality. The relative risk of all-cause or CV mortality in those with ABI p0.4 was increased approximately three to five fold compared with those with ABI of 1.00-1.4. A meta-analysis from Ankle-Brachial Index collaboration subdivided the ABI into 10 categories compared with a reference range of 1.11-1.20 for total mortality and CV mortality. For levels of ABI below 1.11, the Hazard Ratios increased consistently with decreasing ABI in both men and women. 22 All the data showed that those with a low ABI value would be at high risk of death. Our research also confirmed the finding of foreign epidemiological studies about the relationship between ABI and all-cause and CV mortality. The Chinese ankle-brachial index cohort study X Li et al ABI is a potentially strong tool for prediction of CV risk. It has the advantage of ease of use in the primary care clinical practice to identify individuals at high risk. Even a relatively crude method of assessing a diminished circulation to the foot has great predictive value. Recently, guidelines from American Heart Association/American College of Cardiology and European Society of Cardiology have suggested that the ABI should be used to evaluate CV risk. 12, 23 Those guidelines and our Chinese research can provide important information to cardiologists to use ABI, an easy tool to identify those at CV risk.
Our study has several limitations. First, the duration of follow-up is only 3 years and further study is required. Second, 14% of the participants were lost during the follow-up because of the changes of telephone number or family address. If not, we could have got more precise results. Third, all the participants were inpatients at high risk of atherosclerosis; hence, our study cannot represent the general population.
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